nodes	percent_of_prediction	percent_of_DWPC	metapath
Nateglinide—PPARG—psoriasis	0.38	1	CbGaD
Nateglinide—UGT1A9—Mycophenolic acid—psoriasis	0.0846	0.17	CbGbCtD
Nateglinide—UGT1A9—Mycophenolate mofetil—psoriasis	0.0473	0.0948	CbGbCtD
Nateglinide—SLC16A1—Methotrexate—psoriasis	0.033	0.0662	CbGbCtD
Nateglinide—ALB—Acitretin—psoriasis	0.0313	0.0628	CbGbCtD
Nateglinide—CYP3A5—Beclomethasone—psoriasis	0.0296	0.0594	CbGbCtD
Nateglinide—ABCC4—Methotrexate—psoriasis	0.0159	0.0318	CbGbCtD
Nateglinide—ALB—Mycophenolate mofetil—psoriasis	0.0147	0.0294	CbGbCtD
Nateglinide—CYP2D6—Hydroxyurea—psoriasis	0.0138	0.0276	CbGbCtD
Nateglinide—SLC22A6—Cyclosporine—psoriasis	0.013	0.0262	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0126	0.0253	CbGbCtD
Nateglinide—CYP3A7—Hydrocortisone—psoriasis	0.0126	0.0253	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0119	0.0239	CbGbCtD
Nateglinide—CYP3A7—Cyclosporine—psoriasis	0.0119	0.0239	CbGbCtD
Nateglinide—CYP3A5—Mycophenolate mofetil—psoriasis	0.0118	0.0236	CbGbCtD
Nateglinide—ALB—Prednisone—psoriasis	0.0117	0.0235	CbGbCtD
Nateglinide—CYP3A4—Calcitriol—psoriasis	0.0103	0.0206	CbGbCtD
Nateglinide—CYP3A5—Hydrocortisone—psoriasis	0.00946	0.019	CbGbCtD
Nateglinide—CYP2C9—Cholecalciferol—psoriasis	0.00912	0.0183	CbGbCtD
Nateglinide—CYP3A5—Cyclosporine—psoriasis	0.00893	0.0179	CbGbCtD
Nateglinide—CYP2D6—Cholecalciferol—psoriasis	0.00834	0.0167	CbGbCtD
Nateglinide—CYP3A4—Methoxsalen—psoriasis	0.008	0.016	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00784	0.0157	CbGbCtD
Nateglinide—CYP3A7—Dexamethasone—psoriasis	0.00784	0.0157	CbGbCtD
Nateglinide—SLC22A6—Methotrexate—psoriasis	0.0069	0.0138	CbGbCtD
Nateglinide—CYP2C9—Cyclosporine—psoriasis	0.00599	0.012	CbGbCtD
Nateglinide—CYP3A5—Dexamethasone—psoriasis	0.00588	0.0118	CbGbCtD
Nateglinide—ALB—Methotrexate—psoriasis	0.00588	0.0118	CbGbCtD
Nateglinide—CYP2D6—Cyclosporine—psoriasis	0.00548	0.011	CbGbCtD
Nateglinide—CYP3A4—Cholecalciferol—psoriasis	0.0053	0.0106	CbGbCtD
Nateglinide—CYP3A4—Mycophenolate mofetil—psoriasis	0.0046	0.00921	CbGbCtD
Nateglinide—CYP3A4—Triamcinolone—psoriasis	0.0046	0.00921	CbGbCtD
Nateglinide—CYP2C9—Dexamethasone—psoriasis	0.00394	0.00791	CbGbCtD
Nateglinide—CYP3A4—Betamethasone—psoriasis	0.00394	0.0079	CbGbCtD
Nateglinide—CYP3A4—Prednisolone—psoriasis	0.00389	0.0078	CbGbCtD
Nateglinide—CYP3A4—Hydrocortisone—psoriasis	0.00369	0.00739	CbGbCtD
Nateglinide—CYP3A4—Prednisone—psoriasis	0.00367	0.00737	CbGbCtD
Nateglinide—CYP2D6—Dexamethasone—psoriasis	0.00361	0.00723	CbGbCtD
Nateglinide—CYP3A4—Cyclosporine—psoriasis	0.00348	0.00698	CbGbCtD
Nateglinide—CYP3A4—Dexamethasone—psoriasis	0.00229	0.0046	CbGbCtD
Nateglinide—PPARG—dermis—psoriasis	0.000735	0.344	CbGeAlD
Nateglinide—Spirapril—ACE—psoriasis	0.00066	0.163	CrCbGaD
Nateglinide—Mitiglinide—PPARG—psoriasis	0.00063	0.156	CrCbGaD
Nateglinide—Cilazapril—ACE—psoriasis	0.000588	0.146	CrCbGaD
Nateglinide—Lisinopril—ACE—psoriasis	0.000588	0.146	CrCbGaD
Nateglinide—Trandolapril—ACE—psoriasis	0.00057	0.141	CrCbGaD
Nateglinide—Ramipril—ACE—psoriasis	0.00057	0.141	CrCbGaD
Nateglinide—ORM1—vertebral column—psoriasis	0.000539	0.253	CbGeAlD
Nateglinide—Enalapril—ACE—psoriasis	0.000432	0.107	CrCbGaD
Nateglinide—Increased appetite—Dexamethasone—psoriasis	0.000289	0.00302	CcSEcCtD
Nateglinide—Increased appetite—Betamethasone—psoriasis	0.000289	0.00302	CcSEcCtD
Nateglinide—Hepatic enzyme increased—Methotrexate—psoriasis	0.000288	0.00301	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Cyclosporine—psoriasis	0.000287	0.003	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Acitretin—psoriasis	0.000285	0.00298	CcSEcCtD
Nateglinide—Fatigue—Acitretin—psoriasis	0.000285	0.00298	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.000284	0.00297	CcSEcCtD
Nateglinide—Dizziness—Methoxsalen—psoriasis	0.000275	0.00288	CcSEcCtD
Nateglinide—Sweating increased—Prednisolone—psoriasis	0.000274	0.00286	CcSEcCtD
Nateglinide—Hypersensitivity—Calcitriol—psoriasis	0.000274	0.00286	CcSEcCtD
Nateglinide—Osteoarthritis—Betamethasone—psoriasis	0.000271	0.00284	CcSEcCtD
Nateglinide—Osteoarthritis—Dexamethasone—psoriasis	0.000271	0.00284	CcSEcCtD
Nateglinide—Gastrointestinal pain—Acitretin—psoriasis	0.00027	0.00282	CcSEcCtD
Nateglinide—Neuropathy peripheral—Cyclosporine—psoriasis	0.00027	0.00282	CcSEcCtD
Nateglinide—Jaundice—Cyclosporine—psoriasis	0.000269	0.00281	CcSEcCtD
Nateglinide—Sweating increased—Hydrocortisone—psoriasis	0.000268	0.0028	CcSEcCtD
Nateglinide—Asthenia—Calcitriol—psoriasis	0.000266	0.00278	CcSEcCtD
Nateglinide—Malnutrition—Mycophenolic acid—psoriasis	0.000266	0.00278	CcSEcCtD
Nateglinide—Neuropathy peripheral—Mycophenolate mofetil—psoriasis	0.000263	0.00275	CcSEcCtD
Nateglinide—Pruritus—Calcitriol—psoriasis	0.000263	0.00274	CcSEcCtD
Nateglinide—Rash—Methoxsalen—psoriasis	0.000263	0.00274	CcSEcCtD
Nateglinide—Dermatitis—Methoxsalen—psoriasis	0.000262	0.00274	CcSEcCtD
Nateglinide—Urticaria—Acitretin—psoriasis	0.000262	0.00274	CcSEcCtD
Nateglinide—Jaundice—Mycophenolate mofetil—psoriasis	0.000262	0.00274	CcSEcCtD
Nateglinide—Abdominal pain—Acitretin—psoriasis	0.000261	0.00273	CcSEcCtD
Nateglinide—Hepatobiliary disease—Cyclosporine—psoriasis	0.000261	0.00272	CcSEcCtD
Nateglinide—Influenza—Triamcinolone—psoriasis	0.000259	0.0027	CcSEcCtD
Nateglinide—Sweating—Mycophenolate mofetil—psoriasis	0.000258	0.00269	CcSEcCtD
Nateglinide—Back pain—Mycophenolic acid—psoriasis	0.000257	0.00269	CcSEcCtD
Nateglinide—Injury—Prednisone—psoriasis	0.000257	0.00269	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Hydrocortisone—psoriasis	0.000255	0.00267	CcSEcCtD
Nateglinide—Hepatobiliary disease—Mycophenolate mofetil—psoriasis	0.000254	0.00266	CcSEcCtD
Nateglinide—Diarrhoea—Calcitriol—psoriasis	0.000254	0.00265	CcSEcCtD
Nateglinide—Sweating increased—Triamcinolone—psoriasis	0.000252	0.00263	CcSEcCtD
Nateglinide—Increased appetite—Prednisone—psoriasis	0.000252	0.00263	CcSEcCtD
Nateglinide—Tremor—Mycophenolic acid—psoriasis	0.000249	0.00261	CcSEcCtD
Nateglinide—Bronchitis—Triamcinolone—psoriasis	0.000249	0.0026	CcSEcCtD
Nateglinide—Nausea—Methoxsalen—psoriasis	0.000247	0.00259	CcSEcCtD
Nateglinide—Urine output increased—Methotrexate—psoriasis	0.000246	0.00257	CcSEcCtD
Nateglinide—Neuropathy peripheral—Prednisolone—psoriasis	0.000246	0.00257	CcSEcCtD
Nateglinide—Hypersensitivity—Acitretin—psoriasis	0.000243	0.00254	CcSEcCtD
Nateglinide—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.000243	0.00254	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Triamcinolone—psoriasis	0.00024	0.00251	CcSEcCtD
Nateglinide—Neuropathy peripheral—Hydrocortisone—psoriasis	0.00024	0.00251	CcSEcCtD
Nateglinide—Oedema peripheral—Mycophenolate mofetil—psoriasis	0.000238	0.00248	CcSEcCtD
Nateglinide—Asthenia—Acitretin—psoriasis	0.000237	0.00248	CcSEcCtD
Nateglinide—Osteoarthritis—Prednisone—psoriasis	0.000236	0.00247	CcSEcCtD
Nateglinide—Vomiting—Calcitriol—psoriasis	0.000236	0.00247	CcSEcCtD
Nateglinide—Palpitations—Mycophenolic acid—psoriasis	0.000235	0.00246	CcSEcCtD
Nateglinide—Rash—Calcitriol—psoriasis	0.000234	0.00245	CcSEcCtD
Nateglinide—Dermatitis—Calcitriol—psoriasis	0.000234	0.00244	CcSEcCtD
Nateglinide—Pruritus—Acitretin—psoriasis	0.000234	0.00244	CcSEcCtD
Nateglinide—Pruritus—Fluocinolone Acetonide—psoriasis	0.000233	0.00244	CcSEcCtD
Nateglinide—Cough—Mycophenolic acid—psoriasis	0.000232	0.00243	CcSEcCtD
Nateglinide—Sweating increased—Betamethasone—psoriasis	0.000229	0.00239	CcSEcCtD
Nateglinide—Sweating increased—Dexamethasone—psoriasis	0.000229	0.00239	CcSEcCtD
Nateglinide—Dyspepsia—Hydroxyurea—psoriasis	0.000228	0.00239	CcSEcCtD
Nateglinide—Diarrhoea—Acitretin—psoriasis	0.000226	0.00236	CcSEcCtD
Nateglinide—Neuropathy peripheral—Triamcinolone—psoriasis	0.000226	0.00236	CcSEcCtD
Nateglinide—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000225	0.00235	CcSEcCtD
Nateglinide—Polyuria—Methotrexate—psoriasis	0.000225	0.00235	CcSEcCtD
Nateglinide—PPARG—endothelium—psoriasis	0.000224	0.105	CbGeAlD
Nateglinide—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000224	0.00234	CcSEcCtD
Nateglinide—Fatigue—Hydroxyurea—psoriasis	0.000224	0.00234	CcSEcCtD
Nateglinide—Nausea—Calcitriol—psoriasis	0.000221	0.0023	CcSEcCtD
Nateglinide—Dizziness—Acitretin—psoriasis	0.000218	0.00228	CcSEcCtD
Nateglinide—Dizziness—Fluocinolone Acetonide—psoriasis	0.000218	0.00228	CcSEcCtD
Nateglinide—Malnutrition—Cyclosporine—psoriasis	0.000215	0.00225	CcSEcCtD
Nateglinide—Malnutrition—Mycophenolate mofetil—psoriasis	0.00021	0.00219	CcSEcCtD
Nateglinide—Vomiting—Acitretin—psoriasis	0.00021	0.00219	CcSEcCtD
Nateglinide—Hyperhidrosis—Mycophenolic acid—psoriasis	0.00021	0.00219	CcSEcCtD
Nateglinide—Vomiting—Fluocinolone Acetonide—psoriasis	0.000209	0.00219	CcSEcCtD
Nateglinide—Rash—Acitretin—psoriasis	0.000208	0.00218	CcSEcCtD
Nateglinide—Dermatitis—Acitretin—psoriasis	0.000208	0.00217	CcSEcCtD
Nateglinide—Rash—Fluocinolone Acetonide—psoriasis	0.000208	0.00217	CcSEcCtD
Nateglinide—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000208	0.00217	CcSEcCtD
Nateglinide—Neuropathy peripheral—Dexamethasone—psoriasis	0.000205	0.00214	CcSEcCtD
Nateglinide—Neuropathy peripheral—Betamethasone—psoriasis	0.000205	0.00214	CcSEcCtD
Nateglinide—Back pain—Mycophenolate mofetil—psoriasis	0.000203	0.00212	CcSEcCtD
Nateglinide—Tremor—Cyclosporine—psoriasis	0.000202	0.00211	CcSEcCtD
Nateglinide—Sweating increased—Prednisone—psoriasis	0.000199	0.00208	CcSEcCtD
Nateglinide—Immune system disorder—Hydrocortisone—psoriasis	0.000199	0.00207	CcSEcCtD
Nateglinide—Osteoarthritis—Methotrexate—psoriasis	0.000198	0.00206	CcSEcCtD
Nateglinide—Tremor—Mycophenolate mofetil—psoriasis	0.000197	0.00206	CcSEcCtD
Nateglinide—Nausea—Acitretin—psoriasis	0.000196	0.00205	CcSEcCtD
Nateglinide—Nausea—Fluocinolone Acetonide—psoriasis	0.000196	0.00204	CcSEcCtD
Nateglinide—Malnutrition—Hydrocortisone—psoriasis	0.000191	0.002	CcSEcCtD
Nateglinide—Dyspepsia—Mycophenolic acid—psoriasis	0.000191	0.002	CcSEcCtD
Nateglinide—Hypersensitivity—Hydroxyurea—psoriasis	0.000191	0.002	CcSEcCtD
Nateglinide—Cough—Cyclosporine—psoriasis	0.000188	0.00196	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000188	0.00196	CcSEcCtD
Nateglinide—Fatigue—Mycophenolic acid—psoriasis	0.000187	0.00196	CcSEcCtD
Nateglinide—Asthenia—Hydroxyurea—psoriasis	0.000186	0.00194	CcSEcCtD
Nateglinide—Palpitations—Mycophenolate mofetil—psoriasis	0.000186	0.00194	CcSEcCtD
Nateglinide—Cough—Mycophenolate mofetil—psoriasis	0.000183	0.00192	CcSEcCtD
Nateglinide—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000179	0.00924	CbGpPWpGaD
Nateglinide—Neuropathy peripheral—Prednisone—psoriasis	0.000179	0.00187	CcSEcCtD
Nateglinide—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000178	0.00186	CcSEcCtD
Nateglinide—Diarrhoea—Hydroxyurea—psoriasis	0.000177	0.00185	CcSEcCtD
Nateglinide—Back pain—Triamcinolone—psoriasis	0.000174	0.00182	CcSEcCtD
Nateglinide—PPARG—Transcriptional regulation of white adipocyte differentiation—CARM1—psoriasis	0.000174	0.00896	CbGpPWpGaD
Nateglinide—Abdominal pain—Mycophenolic acid—psoriasis	0.000172	0.00179	CcSEcCtD
Nateglinide—Dizziness—Hydroxyurea—psoriasis	0.000172	0.00179	CcSEcCtD
Nateglinide—Hyperhidrosis—Cyclosporine—psoriasis	0.00017	0.00178	CcSEcCtD
Nateglinide—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000166	0.00173	CcSEcCtD
Nateglinide—Vomiting—Hydroxyurea—psoriasis	0.000165	0.00172	CcSEcCtD
Nateglinide—Rash—Hydroxyurea—psoriasis	0.000164	0.00171	CcSEcCtD
Nateglinide—Dermatitis—Hydroxyurea—psoriasis	0.000163	0.00171	CcSEcCtD
Nateglinide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000161	0.00832	CbGpPWpGaD
Nateglinide—UGT1A9—Biological oxidations—CYP2S1—psoriasis	0.000161	0.00829	CbGpPWpGaD
Nateglinide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00016	0.00825	CbGpPWpGaD
Nateglinide—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000159	0.00821	CbGpPWpGaD
Nateglinide—Upper respiratory tract infection—Methotrexate—psoriasis	0.000159	0.00166	CcSEcCtD
Nateglinide—UGT1A9—Metapathway biotransformation—CYP2S1—psoriasis	0.000158	0.00818	CbGpPWpGaD
Nateglinide—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000158	0.00814	CbGpPWpGaD
Nateglinide—Cough—Triamcinolone—psoriasis	0.000157	0.00164	CcSEcCtD
Nateglinide—Asthenia—Mycophenolic acid—psoriasis	0.000156	0.00163	CcSEcCtD
Nateglinide—Dyspepsia—Cyclosporine—psoriasis	0.000155	0.00162	CcSEcCtD
Nateglinide—Hyperhidrosis—Prednisolone—psoriasis	0.000155	0.00162	CcSEcCtD
Nateglinide—Nausea—Hydroxyurea—psoriasis	0.000154	0.00161	CcSEcCtD
Nateglinide—Pruritus—Mycophenolic acid—psoriasis	0.000154	0.00161	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000152	0.00159	CcSEcCtD
Nateglinide—Fatigue—Cyclosporine—psoriasis	0.000152	0.00158	CcSEcCtD
Nateglinide—Hyperhidrosis—Hydrocortisone—psoriasis	0.000151	0.00158	CcSEcCtD
Nateglinide—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000151	0.00158	CcSEcCtD
Nateglinide—Diarrhoea—Mycophenolic acid—psoriasis	0.000149	0.00155	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000148	0.00155	CcSEcCtD
Nateglinide—Immune system disorder—Prednisone—psoriasis	0.000148	0.00154	CcSEcCtD
Nateglinide—Sweating—Methotrexate—psoriasis	0.000146	0.00153	CcSEcCtD
Nateglinide—PPARG—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000144	0.00744	CbGpPWpGaD
Nateglinide—Hepatobiliary disease—Methotrexate—psoriasis	0.000144	0.0015	CcSEcCtD
Nateglinide—Gastrointestinal pain—Cyclosporine—psoriasis	0.000144	0.0015	CcSEcCtD
Nateglinide—Dizziness—Mycophenolic acid—psoriasis	0.000144	0.0015	CcSEcCtD
Nateglinide—ABCC4—Hemostasis—SERPINB8—psoriasis	0.000143	0.00738	CbGpPWpGaD
Nateglinide—Malnutrition—Prednisone—psoriasis	0.000142	0.00149	CcSEcCtD
Nateglinide—Hyperhidrosis—Triamcinolone—psoriasis	0.000142	0.00149	CcSEcCtD
Nateglinide—KCNJ11—Type II diabetes mellitus—TNF—psoriasis	0.000142	0.0073	CbGpPWpGaD
Nateglinide—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.00014	0.00146	CcSEcCtD
Nateglinide—Urticaria—Cyclosporine—psoriasis	0.00014	0.00146	CcSEcCtD
Nateglinide—Abdominal pain—Cyclosporine—psoriasis	0.000139	0.00145	CcSEcCtD
Nateglinide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.000139	0.00715	CbGpPWpGaD
Nateglinide—ALB—HDL-mediated lipid transport—APOE—psoriasis	0.000138	0.00713	CbGpPWpGaD
Nateglinide—Vomiting—Mycophenolic acid—psoriasis	0.000138	0.00144	CcSEcCtD
Nateglinide—Dyspepsia—Hydrocortisone—psoriasis	0.000137	0.00144	CcSEcCtD
Nateglinide—Rash—Mycophenolic acid—psoriasis	0.000137	0.00143	CcSEcCtD
Nateglinide—Dermatitis—Mycophenolic acid—psoriasis	0.000137	0.00143	CcSEcCtD
Nateglinide—Urticaria—Mycophenolate mofetil—psoriasis	0.000136	0.00142	CcSEcCtD
Nateglinide—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000136	0.00142	CcSEcCtD
Nateglinide—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000135	0.00697	CbGpPWpGaD
Nateglinide—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000135	0.00141	CcSEcCtD
Nateglinide—Fatigue—Hydrocortisone—psoriasis	0.000135	0.00141	CcSEcCtD
Nateglinide—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000133	0.00688	CbGpPWpGaD
Nateglinide—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000131	0.00676	CbGpPWpGaD
Nateglinide—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000131	0.00676	CbGpPWpGaD
Nateglinide—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000131	0.00675	CbGpPWpGaD
Nateglinide—PPARG—PPARA activates gene expression—CARM1—psoriasis	0.000131	0.00674	CbGpPWpGaD
Nateglinide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00013	0.00669	CbGpPWpGaD
Nateglinide—Hypersensitivity—Cyclosporine—psoriasis	0.000129	0.00135	CcSEcCtD
Nateglinide—Dyspepsia—Triamcinolone—psoriasis	0.000129	0.00135	CcSEcCtD
Nateglinide—Erythema multiforme—Methotrexate—psoriasis	0.000129	0.00135	CcSEcCtD
Nateglinide—Nausea—Mycophenolic acid—psoriasis	0.000129	0.00135	CcSEcCtD
Nateglinide—Hyperhidrosis—Betamethasone—psoriasis	0.000129	0.00135	CcSEcCtD
Nateglinide—Hyperhidrosis—Dexamethasone—psoriasis	0.000129	0.00135	CcSEcCtD
Nateglinide—PPARG—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000128	0.00659	CbGpPWpGaD
Nateglinide—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000128	0.00133	CcSEcCtD
Nateglinide—Urticaria—Prednisolone—psoriasis	0.000127	0.00133	CcSEcCtD
Nateglinide—Fatigue—Triamcinolone—psoriasis	0.000127	0.00132	CcSEcCtD
Nateglinide—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000126	0.00132	CcSEcCtD
Nateglinide—Asthenia—Cyclosporine—psoriasis	0.000126	0.00132	CcSEcCtD
Nateglinide—Pruritus—Cyclosporine—psoriasis	0.000124	0.0013	CcSEcCtD
Nateglinide—Urticaria—Hydrocortisone—psoriasis	0.000124	0.0013	CcSEcCtD
Nateglinide—Immune system disorder—Methotrexate—psoriasis	0.000123	0.00129	CcSEcCtD
Nateglinide—Abdominal pain—Hydrocortisone—psoriasis	0.000123	0.00129	CcSEcCtD
Nateglinide—Asthenia—Mycophenolate mofetil—psoriasis	0.000123	0.00129	CcSEcCtD
Nateglinide—Pruritus—Mycophenolate mofetil—psoriasis	0.000121	0.00127	CcSEcCtD
Nateglinide—Diarrhoea—Cyclosporine—psoriasis	0.00012	0.00126	CcSEcCtD
Nateglinide—PTGS1—endothelium—psoriasis	0.00012	0.0562	CbGeAlD
Nateglinide—Malnutrition—Methotrexate—psoriasis	0.000119	0.00124	CcSEcCtD
Nateglinide—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000118	0.00611	CbGpPWpGaD
Nateglinide—Hypersensitivity—Prednisolone—psoriasis	0.000118	0.00123	CcSEcCtD
Nateglinide—Dyspepsia—Dexamethasone—psoriasis	0.000117	0.00123	CcSEcCtD
Nateglinide—Dyspepsia—Betamethasone—psoriasis	0.000117	0.00123	CcSEcCtD
Nateglinide—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000117	0.00123	CcSEcCtD
Nateglinide—Urticaria—Triamcinolone—psoriasis	0.000117	0.00122	CcSEcCtD
Nateglinide—Dizziness—Cyclosporine—psoriasis	0.000116	0.00121	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000115	0.0012	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Betamethasone—psoriasis	0.000115	0.0012	CcSEcCtD
Nateglinide—Back pain—Methotrexate—psoriasis	0.000115	0.0012	CcSEcCtD
Nateglinide—Hypersensitivity—Hydrocortisone—psoriasis	0.000115	0.0012	CcSEcCtD
Nateglinide—Fatigue—Dexamethasone—psoriasis	0.000115	0.0012	CcSEcCtD
Nateglinide—Fatigue—Betamethasone—psoriasis	0.000115	0.0012	CcSEcCtD
Nateglinide—Dizziness—Mycophenolate mofetil—psoriasis	0.000113	0.00118	CcSEcCtD
Nateglinide—Hyperhidrosis—Prednisone—psoriasis	0.000112	0.00117	CcSEcCtD
Nateglinide—UGT1A9—PPARA activates gene expression—CARM1—psoriasis	0.000112	0.00579	CbGpPWpGaD
Nateglinide—Asthenia—Hydrocortisone—psoriasis	0.000112	0.00117	CcSEcCtD
Nateglinide—Vomiting—Cyclosporine—psoriasis	0.000112	0.00117	CcSEcCtD
Nateglinide—Rash—Cyclosporine—psoriasis	0.000111	0.00116	CcSEcCtD
Nateglinide—Dermatitis—Cyclosporine—psoriasis	0.000111	0.00116	CcSEcCtD
Nateglinide—Pruritus—Hydrocortisone—psoriasis	0.00011	0.00115	CcSEcCtD
Nateglinide—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.00011	0.00567	CbGpPWpGaD
Nateglinide—Gastrointestinal pain—Dexamethasone—psoriasis	0.000109	0.00114	CcSEcCtD
Nateglinide—Gastrointestinal pain—Betamethasone—psoriasis	0.000109	0.00114	CcSEcCtD
Nateglinide—Vomiting—Mycophenolate mofetil—psoriasis	0.000109	0.00114	CcSEcCtD
Nateglinide—Hypersensitivity—Triamcinolone—psoriasis	0.000108	0.00113	CcSEcCtD
Nateglinide—Rash—Mycophenolate mofetil—psoriasis	0.000108	0.00113	CcSEcCtD
Nateglinide—Dermatitis—Mycophenolate mofetil—psoriasis	0.000108	0.00113	CcSEcCtD
Nateglinide—Diarrhoea—Hydrocortisone—psoriasis	0.000107	0.00112	CcSEcCtD
Nateglinide—Urticaria—Dexamethasone—psoriasis	0.000106	0.00111	CcSEcCtD
Nateglinide—Urticaria—Betamethasone—psoriasis	0.000106	0.00111	CcSEcCtD
Nateglinide—Dizziness—Prednisolone—psoriasis	0.000106	0.0011	CcSEcCtD
Nateglinide—Asthenia—Triamcinolone—psoriasis	0.000106	0.0011	CcSEcCtD
Nateglinide—Abdominal pain—Betamethasone—psoriasis	0.000105	0.0011	CcSEcCtD
Nateglinide—Abdominal pain—Dexamethasone—psoriasis	0.000105	0.0011	CcSEcCtD
Nateglinide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000105	0.00544	CbGpPWpGaD
Nateglinide—PPARG—Transcription factor regulation in adipogenesis—TNF—psoriasis	0.000105	0.0054	CbGpPWpGaD
Nateglinide—Nausea—Cyclosporine—psoriasis	0.000104	0.00109	CcSEcCtD
Nateglinide—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000104	0.00537	CbGpPWpGaD
Nateglinide—Pruritus—Triamcinolone—psoriasis	0.000104	0.00109	CcSEcCtD
Nateglinide—Cough—Methotrexate—psoriasis	0.000104	0.00108	CcSEcCtD
Nateglinide—KCNJ11—tendon—psoriasis	0.000104	0.0486	CbGeAlD
Nateglinide—ABCC4—NRF2 pathway—TGFA—psoriasis	0.000103	0.00534	CbGpPWpGaD
Nateglinide—Dizziness—Hydrocortisone—psoriasis	0.000103	0.00108	CcSEcCtD
Nateglinide—Dyspepsia—Prednisone—psoriasis	0.000102	0.00107	CcSEcCtD
Nateglinide—Nausea—Mycophenolate mofetil—psoriasis	0.000102	0.00106	CcSEcCtD
Nateglinide—Rash—Prednisolone—psoriasis	0.000101	0.00105	CcSEcCtD
Nateglinide—Dermatitis—Prednisolone—psoriasis	0.000101	0.00105	CcSEcCtD
Nateglinide—Fatigue—Prednisone—psoriasis	0.0001	0.00105	CcSEcCtD
Nateglinide—Vomiting—Hydrocortisone—psoriasis	9.93e-05	0.00104	CcSEcCtD
Nateglinide—Rash—Hydrocortisone—psoriasis	9.85e-05	0.00103	CcSEcCtD
Nateglinide—Dermatitis—Hydrocortisone—psoriasis	9.84e-05	0.00103	CcSEcCtD
Nateglinide—CYP3A5—Biological oxidations—CYP2S1—psoriasis	9.77e-05	0.00504	CbGpPWpGaD
Nateglinide—Dizziness—Triamcinolone—psoriasis	9.72e-05	0.00102	CcSEcCtD
Nateglinide—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	9.63e-05	0.00497	CbGpPWpGaD
Nateglinide—PPARG—skin of body—psoriasis	9.58e-05	0.0449	CbGeAlD
Nateglinide—Asthenia—Dexamethasone—psoriasis	9.57e-05	0.001	CcSEcCtD
Nateglinide—Asthenia—Betamethasone—psoriasis	9.57e-05	0.001	CcSEcCtD
Nateglinide—Gastrointestinal pain—Prednisone—psoriasis	9.5e-05	0.000993	CcSEcCtD
Nateglinide—Nausea—Prednisolone—psoriasis	9.5e-05	0.000992	CcSEcCtD
Nateglinide—Pruritus—Dexamethasone—psoriasis	9.44e-05	0.000986	CcSEcCtD
Nateglinide—Pruritus—Betamethasone—psoriasis	9.44e-05	0.000986	CcSEcCtD
Nateglinide—Hyperhidrosis—Methotrexate—psoriasis	9.39e-05	0.000981	CcSEcCtD
Nateglinide—Vomiting—Triamcinolone—psoriasis	9.35e-05	0.000977	CcSEcCtD
Nateglinide—Nausea—Hydrocortisone—psoriasis	9.28e-05	0.000969	CcSEcCtD
Nateglinide—Rash—Triamcinolone—psoriasis	9.27e-05	0.000969	CcSEcCtD
Nateglinide—Dermatitis—Triamcinolone—psoriasis	9.26e-05	0.000968	CcSEcCtD
Nateglinide—Urticaria—Prednisone—psoriasis	9.23e-05	0.000965	CcSEcCtD
Nateglinide—Abdominal pain—Prednisone—psoriasis	9.19e-05	0.00096	CcSEcCtD
Nateglinide—SLC16A1—SLC-mediated transmembrane transport—CP—psoriasis	9.17e-05	0.00473	CbGpPWpGaD
Nateglinide—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	9.15e-05	0.00472	CbGpPWpGaD
Nateglinide—Diarrhoea—Betamethasone—psoriasis	9.13e-05	0.000954	CcSEcCtD
Nateglinide—Diarrhoea—Dexamethasone—psoriasis	9.13e-05	0.000954	CcSEcCtD
Nateglinide—UGT1A9—NRF2 pathway—TGFA—psoriasis	8.94e-05	0.00462	CbGpPWpGaD
Nateglinide—Dizziness—Dexamethasone—psoriasis	8.82e-05	0.000922	CcSEcCtD
Nateglinide—Dizziness—Betamethasone—psoriasis	8.82e-05	0.000922	CcSEcCtD
Nateglinide—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	8.8e-05	0.00454	CbGpPWpGaD
Nateglinide—Nausea—Triamcinolone—psoriasis	8.73e-05	0.000913	CcSEcCtD
Nateglinide—SLC16A1—tendon—psoriasis	8.69e-05	0.0407	CbGeAlD
Nateglinide—SLC15A2—SLC-mediated transmembrane transport—CP—psoriasis	8.64e-05	0.00446	CbGpPWpGaD
Nateglinide—Hypersensitivity—Prednisone—psoriasis	8.56e-05	0.000895	CcSEcCtD
Nateglinide—Dyspepsia—Methotrexate—psoriasis	8.55e-05	0.000893	CcSEcCtD
Nateglinide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	8.55e-05	0.00441	CbGpPWpGaD
Nateglinide—Vomiting—Dexamethasone—psoriasis	8.48e-05	0.000886	CcSEcCtD
Nateglinide—Vomiting—Betamethasone—psoriasis	8.48e-05	0.000886	CcSEcCtD
Nateglinide—PPARG—Transcription factor regulation in adipogenesis—IL6—psoriasis	8.44e-05	0.00436	CbGpPWpGaD
Nateglinide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	8.43e-05	0.00435	CbGpPWpGaD
Nateglinide—Rash—Betamethasone—psoriasis	8.41e-05	0.000879	CcSEcCtD
Nateglinide—Rash—Dexamethasone—psoriasis	8.41e-05	0.000879	CcSEcCtD
Nateglinide—Dermatitis—Betamethasone—psoriasis	8.41e-05	0.000878	CcSEcCtD
Nateglinide—Dermatitis—Dexamethasone—psoriasis	8.41e-05	0.000878	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Methotrexate—psoriasis	8.38e-05	0.000876	CcSEcCtD
Nateglinide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	8.38e-05	0.00432	CbGpPWpGaD
Nateglinide—Fatigue—Methotrexate—psoriasis	8.37e-05	0.000875	CcSEcCtD
Nateglinide—PPARG—Signaling events mediated by HDAC Class I—NFKBIA—psoriasis	8.35e-05	0.00431	CbGpPWpGaD
Nateglinide—Asthenia—Prednisone—psoriasis	8.34e-05	0.000871	CcSEcCtD
Nateglinide—PPARG—Transcriptional regulation of white adipocyte differentiation—LEP—psoriasis	8.3e-05	0.00428	CbGpPWpGaD
Nateglinide—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	8.24e-05	0.00425	CbGpPWpGaD
Nateglinide—Pruritus—Prednisone—psoriasis	8.22e-05	0.000859	CcSEcCtD
Nateglinide—SLC15A1—SLC-mediated transmembrane transport—CP—psoriasis	8.02e-05	0.00414	CbGpPWpGaD
Nateglinide—Diarrhoea—Prednisone—psoriasis	7.95e-05	0.000831	CcSEcCtD
Nateglinide—Gastrointestinal pain—Methotrexate—psoriasis	7.94e-05	0.00083	CcSEcCtD
Nateglinide—ALB—Lipoprotein metabolism—APOE—psoriasis	7.94e-05	0.0041	CbGpPWpGaD
Nateglinide—Nausea—Betamethasone—psoriasis	7.93e-05	0.000828	CcSEcCtD
Nateglinide—Nausea—Dexamethasone—psoriasis	7.93e-05	0.000828	CcSEcCtD
Nateglinide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	7.79e-05	0.00402	CbGpPWpGaD
Nateglinide—Urticaria—Methotrexate—psoriasis	7.71e-05	0.000806	CcSEcCtD
Nateglinide—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	7.7e-05	0.00397	CbGpPWpGaD
Nateglinide—Dizziness—Prednisone—psoriasis	7.68e-05	0.000803	CcSEcCtD
Nateglinide—Abdominal pain—Methotrexate—psoriasis	7.68e-05	0.000802	CcSEcCtD
Nateglinide—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	7.57e-05	0.0039	CbGpPWpGaD
Nateglinide—PPARG—Adipogenesis—SOCS1—psoriasis	7.4e-05	0.00382	CbGpPWpGaD
Nateglinide—Vomiting—Prednisone—psoriasis	7.39e-05	0.000772	CcSEcCtD
Nateglinide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.34e-05	0.00379	CbGpPWpGaD
Nateglinide—Rash—Prednisone—psoriasis	7.33e-05	0.000766	CcSEcCtD
Nateglinide—Dermatitis—Prednisone—psoriasis	7.32e-05	0.000765	CcSEcCtD
Nateglinide—PPARG—tendon—psoriasis	7.29e-05	0.0342	CbGeAlD
Nateglinide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	7.24e-05	0.00374	CbGpPWpGaD
Nateglinide—Hypersensitivity—Methotrexate—psoriasis	7.15e-05	0.000748	CcSEcCtD
Nateglinide—Asthenia—Methotrexate—psoriasis	6.97e-05	0.000728	CcSEcCtD
Nateglinide—CYP2D6—Biological oxidations—CYP2S1—psoriasis	6.94e-05	0.00358	CbGpPWpGaD
Nateglinide—Nausea—Prednisone—psoriasis	6.9e-05	0.000721	CcSEcCtD
Nateglinide—CYP2C9—Biological oxidations—CYP2S1—psoriasis	6.88e-05	0.00355	CbGpPWpGaD
Nateglinide—Pruritus—Methotrexate—psoriasis	6.87e-05	0.000718	CcSEcCtD
Nateglinide—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	6.85e-05	0.00353	CbGpPWpGaD
Nateglinide—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	6.79e-05	0.0035	CbGpPWpGaD
Nateglinide—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	6.73e-05	0.00347	CbGpPWpGaD
Nateglinide—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	6.72e-05	0.00347	CbGpPWpGaD
Nateglinide—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	6.65e-05	0.00343	CbGpPWpGaD
Nateglinide—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	6.65e-05	0.00343	CbGpPWpGaD
Nateglinide—Diarrhoea—Methotrexate—psoriasis	6.64e-05	0.000694	CcSEcCtD
Nateglinide—ABCC4—Fluoropyrimidine Activity—TP53—psoriasis	6.63e-05	0.00342	CbGpPWpGaD
Nateglinide—ABCC4—tendon—psoriasis	6.62e-05	0.031	CbGeAlD
Nateglinide—ALB—Hemostasis—SERPINB8—psoriasis	6.47e-05	0.00334	CbGpPWpGaD
Nateglinide—Dizziness—Methotrexate—psoriasis	6.42e-05	0.000671	CcSEcCtD
Nateglinide—PPARG—Gene Expression—TARS—psoriasis	6.38e-05	0.00329	CbGpPWpGaD
Nateglinide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	6.18e-05	0.00319	CbGpPWpGaD
Nateglinide—Vomiting—Methotrexate—psoriasis	6.17e-05	0.000645	CcSEcCtD
Nateglinide—Rash—Methotrexate—psoriasis	6.12e-05	0.00064	CcSEcCtD
Nateglinide—Dermatitis—Methotrexate—psoriasis	6.12e-05	0.000639	CcSEcCtD
Nateglinide—SLC22A6—SLC-mediated transmembrane transport—CP—psoriasis	5.95e-05	0.00307	CbGpPWpGaD
Nateglinide—PPARG—Regulation of retinoblastoma protein—JUN—psoriasis	5.8e-05	0.00299	CbGpPWpGaD
Nateglinide—Nausea—Methotrexate—psoriasis	5.77e-05	0.000603	CcSEcCtD
Nateglinide—SLC16A1—Hemostasis—ITGAL—psoriasis	5.57e-05	0.00288	CbGpPWpGaD
Nateglinide—PPARG—Adipogenesis—LEP—psoriasis	5.46e-05	0.00282	CbGpPWpGaD
Nateglinide—ALB—Folate Metabolism—CAT—psoriasis	5.44e-05	0.00281	CbGpPWpGaD
Nateglinide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	5.42e-05	0.0028	CbGpPWpGaD
Nateglinide—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	5.34e-05	0.00276	CbGpPWpGaD
Nateglinide—PPARG—Signaling events mediated by HDAC Class I—NFKB1—psoriasis	5.33e-05	0.00275	CbGpPWpGaD
Nateglinide—ALB—Vitamin B12 Metabolism—CRP—psoriasis	5.31e-05	0.00274	CbGpPWpGaD
Nateglinide—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	5.27e-05	0.00272	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—NDUFA5—psoriasis	5.25e-05	0.00271	CbGpPWpGaD
Nateglinide—ALB—Vitamin B12 Metabolism—APOE—psoriasis	5.19e-05	0.00268	CbGpPWpGaD
Nateglinide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.12e-05	0.00264	CbGpPWpGaD
Nateglinide—PTGS1—skin of body—psoriasis	5.12e-05	0.024	CbGeAlD
Nateglinide—KCNJ11—Metabolism—NDUFA5—psoriasis	5.09e-05	0.00263	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—NDUFA5—psoriasis	5.01e-05	0.00259	CbGpPWpGaD
Nateglinide—ALB—Folate Metabolism—IL4—psoriasis	4.99e-05	0.00258	CbGpPWpGaD
Nateglinide—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.98e-05	0.00257	CbGpPWpGaD
Nateglinide—PPARG—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	4.94e-05	0.00255	CbGpPWpGaD
Nateglinide—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	4.91e-05	0.00253	CbGpPWpGaD
Nateglinide—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	4.88e-05	0.00252	CbGpPWpGaD
Nateglinide—ABCC8—Transmembrane transport of small molecules—CP—psoriasis	4.88e-05	0.00252	CbGpPWpGaD
Nateglinide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.84e-05	0.0025	CbGpPWpGaD
Nateglinide—PPARG—Signaling events mediated by HDAC Class I—STAT3—psoriasis	4.79e-05	0.00247	CbGpPWpGaD
Nateglinide—UGT1A9—PPARA activates gene expression—PPARG—psoriasis	4.67e-05	0.00241	CbGpPWpGaD
Nateglinide—SLC16A1—Transmembrane transport of small molecules—CP—psoriasis	4.66e-05	0.0024	CbGpPWpGaD
Nateglinide—ABCC8—Transmembrane transport of small molecules—CARM1—psoriasis	4.65e-05	0.0024	CbGpPWpGaD
Nateglinide—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	4.57e-05	0.00236	CbGpPWpGaD
Nateglinide—CYP3A4—Biological oxidations—CYP2S1—psoriasis	4.54e-05	0.00234	CbGpPWpGaD
Nateglinide—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	4.48e-05	0.00231	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—CYP2S1—psoriasis	4.46e-05	0.0023	CbGpPWpGaD
Nateglinide—SLC16A1—Transmembrane transport of small molecules—CARM1—psoriasis	4.45e-05	0.00229	CbGpPWpGaD
Nateglinide—SLC15A2—Transmembrane transport of small molecules—CP—psoriasis	4.39e-05	0.00227	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—CYP2S1—psoriasis	4.33e-05	0.00223	CbGpPWpGaD
Nateglinide—ABCC4—Platelet degranulation—VEGFA—psoriasis	4.32e-05	0.00223	CbGpPWpGaD
Nateglinide—ALB—Selenium Micronutrient Network—CAT—psoriasis	4.32e-05	0.00223	CbGpPWpGaD
Nateglinide—ALB—Folate Metabolism—CRP—psoriasis	4.32e-05	0.00223	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—CYP2S1—psoriasis	4.26e-05	0.0022	CbGpPWpGaD
Nateglinide—SLC15A2—Transmembrane transport of small molecules—CARM1—psoriasis	4.19e-05	0.00216	CbGpPWpGaD
Nateglinide—PPARG—Generic Transcription Pathway—CARM1—psoriasis	4.17e-05	0.00215	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—ITGAL—psoriasis	4.16e-05	0.00214	CbGpPWpGaD
Nateglinide—PPARG—Signaling events mediated by HDAC Class I—TNF—psoriasis	4.14e-05	0.00214	CbGpPWpGaD
Nateglinide—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	4.11e-05	0.00212	CbGpPWpGaD
Nateglinide—SLC15A1—Transmembrane transport of small molecules—CP—psoriasis	4.07e-05	0.0021	CbGpPWpGaD
Nateglinide—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	4e-05	0.00207	CbGpPWpGaD
Nateglinide—ALB—Folate Metabolism—ICAM1—psoriasis	3.97e-05	0.00205	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—CARM1—psoriasis	3.93e-05	0.00203	CbGpPWpGaD
Nateglinide—CYP3A4—Tryptophan metabolism—CAT—psoriasis	3.92e-05	0.00202	CbGpPWpGaD
Nateglinide—PTGS1—tendon—psoriasis	3.9e-05	0.0183	CbGeAlD
Nateglinide—SLC15A1—Transmembrane transport of small molecules—CARM1—psoriasis	3.89e-05	0.00201	CbGpPWpGaD
Nateglinide—PPARG—Circadian rythm related genes—LEP—psoriasis	3.85e-05	0.00199	CbGpPWpGaD
Nateglinide—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—psoriasis	3.84e-05	0.00198	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—NDUFA5—psoriasis	3.76e-05	0.00194	CbGpPWpGaD
Nateglinide—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	3.73e-05	0.00193	CbGpPWpGaD
Nateglinide—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	3.71e-05	0.00191	CbGpPWpGaD
Nateglinide—PPARG—Circadian rythm related genes—NOS2—psoriasis	3.59e-05	0.00185	CbGpPWpGaD
Nateglinide—PPARG—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.51e-05	0.00181	CbGpPWpGaD
Nateglinide—ABCC4—Transmembrane transport of small molecules—CP—psoriasis	3.47e-05	0.00179	CbGpPWpGaD
Nateglinide—ALB—Selenium Micronutrient Network—CRP—psoriasis	3.43e-05	0.00177	CbGpPWpGaD
Nateglinide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.38e-05	0.00174	CbGpPWpGaD
Nateglinide—ABCC4—Transmembrane transport of small molecules—CARM1—psoriasis	3.31e-05	0.00171	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—NDUFA5—psoriasis	3.23e-05	0.00167	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—CYP2S1—psoriasis	3.2e-05	0.00165	CbGpPWpGaD
Nateglinide—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	3.15e-05	0.00163	CbGpPWpGaD
Nateglinide—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	3.15e-05	0.00163	CbGpPWpGaD
Nateglinide—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	3.11e-05	0.0016	CbGpPWpGaD
Nateglinide—ALB—SLC-mediated transmembrane transport—CP—psoriasis	3.09e-05	0.0016	CbGpPWpGaD
Nateglinide—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	3.09e-05	0.00159	CbGpPWpGaD
Nateglinide—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	3.02e-05	0.00156	CbGpPWpGaD
Nateglinide—ALB—Folate Metabolism—IFNG—psoriasis	3.02e-05	0.00156	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.01e-05	0.00155	CbGpPWpGaD
Nateglinide—PPARG—Adipogenesis—STAT3—psoriasis	2.92e-05	0.00151	CbGpPWpGaD
Nateglinide—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	2.89e-05	0.00149	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—CYP2S1—psoriasis	2.75e-05	0.00142	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—NDUFA5—psoriasis	2.72e-05	0.0014	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—NDUFA5—psoriasis	2.63e-05	0.00136	CbGpPWpGaD
Nateglinide—PPARG—Adipogenesis—TNF—psoriasis	2.52e-05	0.0013	CbGpPWpGaD
Nateglinide—ALB—Folate Metabolism—NFKB1—psoriasis	2.51e-05	0.0013	CbGpPWpGaD
Nateglinide—PPARG—Generic Transcription Pathway—VDR—psoriasis	2.49e-05	0.00129	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.46e-05	0.00127	CbGpPWpGaD
Nateglinide—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	2.42e-05	0.00125	CbGpPWpGaD
Nateglinide—ALB—Vitamin B12 Metabolism—TNF—psoriasis	2.4e-05	0.00124	CbGpPWpGaD
Nateglinide—ALB—Selenium Micronutrient Network—IFNG—psoriasis	2.4e-05	0.00124	CbGpPWpGaD
Nateglinide—PPARG—Circadian rythm related genes—JUN—psoriasis	2.38e-05	0.00123	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—CYP2S1—psoriasis	2.31e-05	0.00119	CbGpPWpGaD
Nateglinide—SLC16A1—Hemostasis—NOS2—psoriasis	2.29e-05	0.00118	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—CYP2S1—psoriasis	2.24e-05	0.00116	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—CARM1—psoriasis	2.18e-05	0.00112	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—CARM1—psoriasis	2.11e-05	0.00109	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—CARM1—psoriasis	2.08e-05	0.00107	CbGpPWpGaD
Nateglinide—PPARG—Adipogenesis—IL6—psoriasis	2.04e-05	0.00105	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—CARM1—psoriasis	2.01e-05	0.00104	CbGpPWpGaD
Nateglinide—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	2e-05	0.00103	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—NDUFA5—psoriasis	1.96e-05	0.00101	CbGpPWpGaD
Nateglinide—ALB—Platelet degranulation—VEGFA—psoriasis	1.95e-05	0.00101	CbGpPWpGaD
Nateglinide—ALB—Folate Metabolism—TNF—psoriasis	1.95e-05	0.00101	CbGpPWpGaD
Nateglinide—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	1.95e-05	0.00101	CbGpPWpGaD
Nateglinide—ALB—Vitamin B12 Metabolism—IL6—psoriasis	1.94e-05	0.001	CbGpPWpGaD
Nateglinide—ABCC4—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.92e-05	0.000989	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—ITGAL—psoriasis	1.88e-05	0.00097	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—LEP—psoriasis	1.88e-05	0.000968	CbGpPWpGaD
Nateglinide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	1.86e-05	0.000961	CbGpPWpGaD
Nateglinide—ALB—Folate Metabolism—TP53—psoriasis	1.72e-05	0.000889	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—NOS2—psoriasis	1.71e-05	0.00088	CbGpPWpGaD
Nateglinide—ALB—Metabolism—NDUFA5—psoriasis	1.69e-05	0.000873	CbGpPWpGaD
Nateglinide—PPARG—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.68e-05	0.000865	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CYP2S1—psoriasis	1.67e-05	0.000862	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.58e-05	0.000814	CbGpPWpGaD
Nateglinide—ALB—Folate Metabolism—IL6—psoriasis	1.58e-05	0.000814	CbGpPWpGaD
Nateglinide—ALB—Transmembrane transport of small molecules—CP—psoriasis	1.57e-05	0.000811	CbGpPWpGaD
Nateglinide—PPARG—Circadian rythm related genes—TP53—psoriasis	1.57e-05	0.000811	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—CARM1—psoriasis	1.56e-05	0.000806	CbGpPWpGaD
Nateglinide—ALB—Selenium Micronutrient Network—TNF—psoriasis	1.55e-05	0.000801	CbGpPWpGaD
Nateglinide—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	1.5e-05	0.000774	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.44e-05	0.000743	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CYP2S1—psoriasis	1.44e-05	0.000742	CbGpPWpGaD
Nateglinide—PPARG—Circadian rythm related genes—IL6—psoriasis	1.44e-05	0.000742	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—TYK2—psoriasis	1.43e-05	0.000739	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NDUFA5—psoriasis	1.4e-05	0.000721	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NDUFA5—psoriasis	1.38e-05	0.000715	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—CARM1—psoriasis	1.34e-05	0.000692	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—CAT—psoriasis	1.34e-05	0.000692	CbGpPWpGaD
Nateglinide—SLC16A1—Hemostasis—VEGFA—psoriasis	1.32e-05	0.000684	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—CAT—psoriasis	1.3e-05	0.000671	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.29e-05	0.000666	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—CAT—psoriasis	1.28e-05	0.000661	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.25e-05	0.000647	CbGpPWpGaD
Nateglinide—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.25e-05	0.000646	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—VDR—psoriasis	1.2e-05	0.000619	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP2S1—psoriasis	1.19e-05	0.000613	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP2S1—psoriasis	1.18e-05	0.000608	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.17e-05	0.000606	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—CARM1—psoriasis	1.13e-05	0.000582	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—NFKB1—psoriasis	1.12e-05	0.000576	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—CARM1—psoriasis	1.09e-05	0.000564	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—APOE—psoriasis	1.04e-05	0.000537	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.02e-05	0.000528	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—VEGFA—psoriasis	1.01e-05	0.000523	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—APOE—psoriasis	1.01e-05	0.000521	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—STAT3—psoriasis	1e-05	0.000517	CbGpPWpGaD
Nateglinide—SLC16A1—Hemostasis—TP53—psoriasis	1e-05	0.000517	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—APOE—psoriasis	9.95e-06	0.000514	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—VEGFA—psoriasis	9.88e-06	0.00051	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—CAT—psoriasis	9.6e-06	0.000496	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NDUFA5—psoriasis	9.13e-06	0.000471	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PPARG—psoriasis	9.07e-06	0.000468	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PPARG—psoriasis	8.79e-06	0.000454	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—TNF—psoriasis	8.68e-06	0.000448	CbGpPWpGaD
Nateglinide—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	8.67e-06	0.000447	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PPARG—psoriasis	8.67e-06	0.000447	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—CAT—psoriasis	8.25e-06	0.000426	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CARM1—psoriasis	8.16e-06	0.000421	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP2S1—psoriasis	7.76e-06	0.000401	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—NOS2—psoriasis	7.72e-06	0.000398	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.54e-06	0.000389	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—TP53—psoriasis	7.46e-06	0.000385	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—APOE—psoriasis	7.46e-06	0.000385	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CARM1—psoriasis	7.02e-06	0.000363	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—IL6—psoriasis	7e-06	0.000361	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—CAT—psoriasis	6.94e-06	0.000358	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—CAT—psoriasis	6.73e-06	0.000347	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.57e-06	0.000339	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—APOE—psoriasis	6.41e-06	0.000331	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.17e-06	0.000318	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CARM1—psoriasis	5.8e-06	0.000299	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CARM1—psoriasis	5.75e-06	0.000297	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PPARG—psoriasis	5.58e-06	0.000288	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—APOE—psoriasis	5.39e-06	0.000278	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.37e-06	0.000277	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—APOE—psoriasis	5.23e-06	0.00027	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CAT—psoriasis	5.02e-06	0.000259	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PPARG—psoriasis	4.7e-06	0.000242	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PPARG—psoriasis	4.55e-06	0.000235	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—VEGFA—psoriasis	4.47e-06	0.000231	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CAT—psoriasis	4.32e-06	0.000223	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—APOE—psoriasis	3.9e-06	0.000201	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CARM1—psoriasis	3.79e-06	0.000196	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CAT—psoriasis	3.57e-06	0.000184	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CAT—psoriasis	3.54e-06	0.000183	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PPARG—psoriasis	3.4e-06	0.000175	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—TP53—psoriasis	3.38e-06	0.000174	CbGpPWpGaD
Nateglinide—ALB—Metabolism—APOE—psoriasis	3.36e-06	0.000173	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PPARG—psoriasis	2.92e-06	0.000151	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—APOE—psoriasis	2.77e-06	0.000143	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—APOE—psoriasis	2.75e-06	0.000142	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PPARG—psoriasis	2.41e-06	0.000125	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PPARG—psoriasis	2.39e-06	0.000124	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CAT—psoriasis	2.33e-06	0.00012	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—APOE—psoriasis	1.81e-06	9.35e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PPARG—psoriasis	1.58e-06	8.15e-05	CbGpPWpGaD
